ライフサイエンスコーパス: serological test

1 tive histological examination and a positive serological test.

2 protein 22 (ADAM22) or ADAM23 was used as a serological test.

3 or GABA(B2) receptor subunits was used as a serological test.

4 able encephalitis that can be diagnosed by a serological test.

5 the urgent need for a specific and sensitive serological test.

6 re currently identified by using culture and serological tests.

7 B. recurrentis and used recombinant GlpQ in serological tests.

8 ositive during the study period using PCR or serological tests.

9 begin therapy shortly after infection using serological tests.

10 istopathology, direct immunofluorescence and serological tests.

11 ofilaremic occult infections, and unreliable serological tests.

12 he usual diagnosis of this disease relies on serological tests.

13 difference was not explained by frequency of serological tests.

14 ires positive results from two different IgG serological tests.

15 cant increase to the pre-test probability of serological tests.

16 transcription-polymerase chain reaction and serological tests.

17 gs add weight to negative microbiological or serological tests.

18 lly infected, and of the cost per sample for serological tests.

19 a combination of self-reported adherence and serological tests.

20 e the efficiency, ease, and effectiveness of serological testing.

21 rvey and underwent home-based phlebotomy for serological testing.

22 itative polymerase chain reaction assays and serological testing.

23 id testing (NAT) are comparable to those for serological testing.

24 tive, and economically viable alternative to serological testing.

25 e Disease recommended a two-step approach to serological testing.

26 t leptospiral serovar Grippotyphosa from the serological testing.

27 both may contribute to the discrepancies in serological testing.

28 tions for both polymerase chain reaction and serological testing.

29 l assessments, and provided biospecimens for serological testing.

30 ibody measurement, assuming sparse access to serological testing.

31 obtained using clinically validated qPCR and serological testing.

32 oV-2 has led to a growing need for expansive serological testing.

33 level infection risk without access to broad serological testing.

34 seases, making it a powerful tool for future serological testing.

35 ion neutralizing assay, the gold standard of serological testing.

36 onths, blood samples were taken for repeated serological testing.

37 miological intervention model that leverages serological tests(6,7) to identify and deploy recovered

38 ty of two PCR tests (groEL and recD) and two serological tests (adsorption enzyme immunoassay [EIA] a

39 questionnaire and provide a blood sample for serological testing against five recently circulating in

40 WDEIA in children cannot be ruled out by serological tests alone.

41 t incorporating rKR95 and rTR18 with rK39 in serological tests amenable to rapid or high-throughput s

42 n (RPR) test with that of the combination of serological testing and an experimental 23S rRNA Trepone

43 revalence of HBV infection was determined by serological testing and analysis among noninstitutionali

44 ant implications when considering widespread serological testing and antibody protection against rein

45 cilitate coronavirus disease 2019 (COVID-19) serological testing and antiviral screening.

46 ns, observing the clinical course, obtaining serological testing and appreciating the MRI features.

47 6 weeks using different antibody assays for serological testing and questionnaires to evaluate risk

48 serogroup level was observed: serotype 29 by serological testing and serotype 35B/D by all WGS-based

49 us and SARS-CoV-2 were inconsistent for both serological testing and testing of explant or biopsy liv

50 within 2 years before and after the date of serological testing and to identify vaccinees.

51 Mathematical models demonstrate that a serological testing and treatment strategy could reduce

52 Serological tests and chemical analysis of the major pol

53 diagnostic use, there are no FDA-authorized serological tests and few laboratory-developed serologic

54 RS-CoV-2 infection using ten high-throughput serological tests and functional neutralisation assays.

55 f patients was thoroughly documented through serological tests and liver biopsy reports.

56 ent viable therapy and even with advances in serological tests and markers, the duodenal biopsy remai

57 and prognostic tests have commonly examined serological tests and new imaging techniques.

58 Serological tests and small bowel biopsy remain the corn

59 e correlations among viruses and vaccines in serological tests and the power of HA sequence in predic

60 included comparing performance of different serological tests and to determine whether the suggested

61 autoimmune disease by histological analysis, serological testing, and clinical recurrence during foll

62 boratory testing, including antigen testing, serological testing, and PCR-based assays.

63 ed using a combination of clinical features, serological tests, and histopathological findings.

64 made by analyzing anti-tTG, anti-DGP, or EMA serological tests, and it is confirmed by biopsy of the

65 Ag in infected patients that can be used in serological tests, and its detection in saliva could be

66 is an immunogenic protein with utility as a serological test antigen for discriminating tick-borne r

67 Serological tests are a powerful tool in the monitoring

68 Serological tests are essential for the control and mana

69 In diagnosing celiac disease (CD), serological tests are highly valuable.

70 roscopy of a perilesional biopsy specimen or serological tests are needed for exact diagnosis.

71 If the serological tests are positive, it only proves that expo

72 vaccines elicit antibody responses that most serological tests are unable to differentiate from an in

73 The serological tests are used to determine non-structural p

74 nvasive methods, including breath, stool and serological tests, are used in the diagnosis of H. pylor

75 his extended spectrum may enhance autoimmune serological testing as an aid to preoperative thymoma di

76 The present model highlights the value of serological testing as part of intervention strategies,

77 Inclusion criteria included: a negative HIV serological test at the screening and study entry, undet

78 Serological testing at the New York State Department of

79 nts with typhoid fever, the sensitivity of a serological test based on the detection of anti-lipopoly

80 Isolates were assigned a capsular type by serological testing based on anticapsular antisera and b

81 avirus 2 infection confirmed by molecular or serological testing before randomisation (ie, modified I

82 In all sites, serological testing blunted subsequent waves of transmis

83 Most diagnosis is based on serological tests, but the lack of a gold standard test

84 Serological tests can be an important complementary appr

85 Serological tests can be used diagnostically and for sur

86 However, only serological tests can determine blood provenance.

87 ross-sectional study was conducted using IgG serological tests collected from April 1 through May 26,

88 ced by HIV-1 vaccines to react with standard serological tests, complicating diagnosis and leading to

89 Serological testing confirmed an infection with Entamoeb

90 Using a transmission model, we examine how serological testing could have enabled seropositive indi

91 at, during established disease, more regular serological testing could illuminate changes relevant to

92 time-polymerase chain reaction (RT-PCR) and serological test data from January and May 2022 to asses

93 We analysed longitudinal PCR and serological testing data from a prospective cohort of 4,

94 omen (n=2421) matched to exposed subjects on serological test date and age (+/-3 years).

95 Additionally, currently available serological tests do not exclude the possibility that po

96 al measurements (e.g., body mass index), and serological tests (e.g., viral load).

97 rovement and standardization of the existing serological tests, enable rational design of novel tests

98 phase, the use of urine samples coupled with serological tests, epidemiologic inquiry, and clinical a

99 and stroke units should be on alert and use serological testing, especially in younger patients or i

100 Serological tests exist but cannot distinguish active VL

101 m causing mycetoma is difficult; no reliable serological test exists but molecular techniques to iden

102 cial need for a rapid and sensitive in vitro serological test for BoNT/A to replace the current in vi

103 We have developed a multiplex serological test for bovine tuberculosis and here we pro

104 ntial as a rapid and sensitive point-of-care serological test for COVID-19.

105 The development of a serological test for foot-and-mouth disease virus (FMDV)

106 lapse, and assess the potential utility of a serological test for radical cure in low transmission se

107 To develop a specific serological test for relapsing fever, we created a genom

108 The current serological test for tularemia is based on agglutination

109 ts screening seropositive had serial monthly serological testing for a maximum of 7 months with the M

110 We performed serological testing for anti-HBs and microRNA-155 and as

111 rvey participants were randomly enrolled for serological testing for anti-measles virus immunoglobuli

112 We discuss the diagnostic value of serological testing for anti-PLA2R and tissue staining f

113 Serological testing for antibodies against transglutamin

114 Serological testing for antibodies is promising for surv

115 Serological testing for antibodies to Ct antigens is pot

116 To simplify serological testing for B. duncani, a proteomics approac

117 The optimal algorithm for implementing serological testing for COVID-19 remains to be determine

118 can address the current gap in point-of-care serological testing for COVID-19.

119 e, epidemiological and clinical studies, and serological testing for dengue vaccine eligibility.

120 VID-19 history and HIV status) and performed serological testing for EBV and CMV using a commercial l

121 sing patients who were H. pylori positive on serological testing for H. pylori IgG-antibodies were ra

122 Diagnosis of HBV infection requires serological testing for HBsAg and for acute infection ad

123 r sexual and social activities and underwent serological testing for herpes simplex virus types 1 and

124 Serological testing for HLA class I antigens was perform

125 a community-based research center, underwent serological testing for human immunodeficiency virus and

126 Serological testing for immunoglobulin G (IgG) antibodie

127 Serological testing for KIR4.1-specific IgG is unlikely

128 could serve as a noninvasive alternative to serological testing for monitoring of SARS-CoV-2 infecti

129 Serological testing for nasopharyngeal carcinoma (NPC) h

130 Using multiplex serological testing for persistent or frequently recurri

131 res careful review of medications taken, and serological testing for possible viral exposure.

132 Serological testing for SARS-CoV-2 IgG antibodies is use

133 ich required daily RT-PCR testing and ad hoc serological testing for SARS-CoV-2 IgG antibodies.

134 Widespread viral and serological testing for severe acute respiratory syndrom

135 Serological testing for syphilis has been impacted by a

136 Serological testing for Trypanosoma cruzi was performed

137 ical formula for the minimum requirements of serological tests for a passport program, which depend o

138 Appropriate use and interpretation of serological tests for assessments of severe acute respir

139 Current serological tests for Helicobacter pylori (HP) infection

140 Serological tests for immunoglobulin G (IgG), IgA, and I

141 Serological tests for pancreatic cancer are little used,

142 The diagnostic accuracy of serological tests for SARS-CoV-2 antibodies varied remar

143 To date, the vast majority of the serological tests for SARS-CoV-2-specific Abs are based

144 ap to guide the choice and interpretation of serological tests for SARS-CoV-2.

145 itative range and reproducibility of current serological tests for severe acute respiratory syndrome

146 Serological tests for the various clinical manifestation

147 As most serological tests for ZIKV focused on envelope and nonst

148 As serological tests for ZIKV primarily focus on envelope (

149 /or conducting epidemiologically appropriate serological tests for zoonotic infections, including tha

150 Serological tests form a vital part of a multifactorial

151 No serological test had predictive value greater than 40% f

152 onstrate the potential benefit of widespread serological testing, had it been implemented in the pre-

153 der different scenarios and assessed whether serological testing has the potential to correct this bi

154 test for microbial diagnosis, with directed serological testing (i.e., Q fever serology, Bartonella

155 In Atlanta, serological testing identified a new virus.

156 PCR amplification and serological testing identified the infecting species as

157 We simulate widespread serological testing in New York City, South Florida, and

158 ven the lower sensitivity and specificity of serological tests in the aged population, clinical suspe

159 study was to assess the performance of these serological tests in the presence of gastric neoplasia.

160 is that the low positive predictive value of serological tests in the setting of low population serop

161 ory diagnosis for Lyme disease is two-tiered serological testing, in which a reactive first-tier enzy

162 surveys and SARS-CoV-2 viral and orthogonal serological testing, including measurement of neutralizi

163 Serological testing indicated moderately active SLE, sup

164 ed the disease after similar challenges, and serological testing indicated that transmitted bacteria

165 Serological tests indicated that HNF-1alpha was present

166 Prior to serological testing, influenza viruses are typically pro

167 ies and will help support the integration of serological testing into disease surveillance platforms.

168 Paired serological testing, involving both acute and convalesce

169 No serological test is 100% accurate, however, and the stan

170 severe clinical disease; however, because no serological test is readily available, patients must und

171 Serological testing is emerging as a powerful tool to pr

172 Sensitive serological testing is essential to estimate the proport

173 in resource-limited settings where access to serological tests is restricted.

174 allenge in developing specific M. genitalium serological tests is the extensive cross-reactivity with

175 The performance of serological tests is usually evaluated at 14-21 days pos

176 HLH and B. henselae through liver biopsy and serological tests led to the patient's recovery.

177 r results suggest that both nucleic acid and serological testing may be needed to determine exposure

178 Combining mucosal TMA testing and serological testing may increase the sensitivity of syph

179 Relying on routine virological and serological testing may not identify exposed children, w

180 Novel serological tests may have prognostic value.

181 as increased the complexity of diagnosis, as serological tests may not distinguish between naturally

182 2 or worse in HPV-naive subcohorts; however, serological testing methods and the HPV DNA criteria use

183 we evaluate the performance of a new leprosy serological test (NDO-LID).

184 Serological testing of 25 (93%) of 27 patients operated

185 Over 4400 patients underwent serological testing of an acute sample for Rickettsia (N

186 Serological testing of donors can identify patients who

187 Serological testing of large representative populations

188 del accurately estimate VES and only require serological testing of participants once, while a Cox mo

189 Serological testing of Singaporeans who received childho

190 e the amount of resources spent on exclusive serological testing of vaccines and make wide spectrum v

191 rological tests and few laboratory-developed serological tests offered.

192 help reduce the sample collection burden of serological testing on both health care systems and indi

193 ut also collect information, ideally through serological testing, on this critical variable.

194 had clinical symptoms and either a positive serological test or a known epidemiological link to a co

195 using ICD codes without confirmation through serological testing or polymerase chain reaction, and we

196 diagnosis cannot be performed using routine serological tests or identification methods.

197 n of syphilis by direct detection methods or serological testing, or both, were included.

198 rase chain reaction testing, bronchial swab, serological testing, or suggestive computed tomography r

199 sults of polymerase chain reaction analysis, serological tests, or antigen tests for SARS-CoV-2 or di

200 Serological testing, outer membrane protein A (ompA) gen

201 nfection cases from Argentina were missed by serological tests, over 21% in Honduras, and an alarming

202 d economical microbead array-based multiplex serological test panels for veterinary use.

203 ve alternative to costly and less accessible serological tests, particularly in resource-limited sett

204 We did serological testing, PCR, and sequence analysis to obtai

205 mall subset (n = 14) had cat scratch disease serological tests performed.

206 Serological tests play an important role in the fight ag

207 f congenital toxoplasmosis and indicate that serological testing provides a promising method for geno

208 Serological testing remains a passive component of the p

209 The median (range) time from a positive serological test result to AIS was 54.5 (0-130) days.

210 rotection, including the correlation between serological test results and risk of reinfection.

211 respiratory symptoms or positive SARS-CoV-2 serological test results confirmed through reverse trans

212 Serological test results for 451 patients with positive

213 llance was limited to the serum sample-based serological test results without going for population-le

214 on were determined by comparison to anti-HCV serological test results, alanine aminotransferase level

215 ease status, the role of viral screening and serological testing, return-to-work considerations for e

216 Serological testing revealed neutralizing antibody respo

217 Serological testing revealed the presence of antibodies

218 Therefore, proper diagnostics such as serological testing should be urgently conducted in furt

219 nor specific, virological and type-specific serological tests should be used routinely.

220 ed by the use of cost-effective confirmatory serological tests, similar standardized tools are not wi

221 rvention, our model suggests that widespread serological testing starting in late 2020 would have ave

222 determine the diagnostic accuracy of various serological testing strategies for (a) identification of

223 We used the results of serological testing studies to estimate the actual numbe

224 for celiac disease were conducted, including serological tests such as Tissue transglutaminase IgA (t

225 Conventional methods for serological testing, such as enzyme-linked immunosorbent

226 -antigen panels in challenging scenarios for serological testing, such as the cross-reactivity presen

227 eved using standardized and widely available serological test systems.

228 A simple and accurate serological test that is capable of detecting asymptomat

229 Detection of the ZIKV is based on serological testing that often shows cross-reactivity wi

230 ENV infection underscore a critical need for serological tests that can discriminate past ZIKV, DENV,

231 Serological tests that identify past infection can be us

232 On serological testing, the polymeric material was shown to

233 is assessed based on changes over months in serological test titres.

234 ptive diagnoses, and performed molecular and serological testing to confirm DENV, CHIKV, ZIKV, or non

235 Given the limited availability of serological testing to date, the seroprevalence of SARS-

236 and March 2020 and necessitating the use of serological testing to determine past infections.

237 Serological testing to evaluate antigen-specific antibod

238 n a demand for highly specific and sensitive serological testing to evaluate seroprevalence and antiv

239 cientific uncertainties regarding the use of serological tests to assure immune status and a public h

240 When considering at least two reactive serological tests to confirm seropositivity, over 12% of

241 NV infection, highlighting a need for better serological tests to discriminate past ZIKV, DENV, and/o

242 rt can serve as an example to prompt earlier serological tests to identify the aetiology in similar c

243 Use of individual-level serological tests to redirect doses to seronegative indi

244 usly documented, by clinical examination and serological testing, to have in utero rubella exposure d

245 In serological test total IgE antibody and Aspergillus spec

246 th relatively high accuracy noninvasively by serological tests, transient elastography, and radiologi

247 Negative rate was 96%, but in validating the serological tests uncovered potential false-negatives fr

248 the hemagglutinin (HA) glycoprotein, classic serological tests used by surveillance laboratories indi

249 stations and difficulty in interpretation of serological tests used to confirm diagnosis and evaluate

250 ng results are now available to Lyme disease serological test users and researchers developing novel

251 We compared the sensitivity of syphilis serological testing using the rapid plasma reagin (RPR)

252 Current design of serological tests utilizes conservative immunoassay appr

253 HIV-1 serological testing was done at each visit.

254 Serological testing was negative for Borreliosis and TBE

255 gy-Hepatology- Nutrition Department, and the serological testing was performed at the Lyon-Sud Hospit

256 PCR and serological testing was performed on 394 individuals.

257 HPV serological testing was performed using competitive Lumi

258 lymerase chain reaction (RT-PCR) analysis or serological testing was used to confirm Ebola virus infe

259 The greatest contribution of IGRA to serological tests was observed in patients with mild dis

260 ca selective culture, genome sequencing, and serological testing were performed on maternal and infan

261 on (PCR) amplification of blood samples, and serological testing were performed to identify the infec

262 Both PCR and serological tests were administered to all study partici

263 Serological tests were also used for diagnosing dengue f

264 Serological tests were conducted on 3698 swine sera, inc

265 ; and 3) the fact that multiple poor-quality serological tests were used to detect SARS-CoV-2 antibod

266 To diagnose celiac disease, serological tests were used, and duodenal biopsy samples

267 indicate that it may be possible to develop serological tests which predict the induction of unfavou

268 expect that the availability of high-quality serological testing will be a key tool in the fight agai

269 h-throughput quantitative anti-spike protein serological testing will likely become increasingly impo

270 nd on serology (any titre) or had a positive serological test with high titres, irrespective of the r

271 Serological testing with the detection of pepsinogen 1 (

272 ntervention was standing orders for syphilis serological testing with viral loads, and control was us

273 Previous serological tests with KS patient sera have detected lyt

274 Serological tests with noninduced (latent) and induced (

275 etrospective studies, mostly on the basis of serological tests, with the problematic cross-reacting a

276 We performed electrophysiological and serological testing within 15 days of symptom onset on 3

277 ggest that the inclusion of both S1 and N in serological testing would capture as many potential SARS